The study of Wu et al. enrolled 223 Taiwanese MDS cases and detected SRSF2 mutation in 34 (14.6%) of investigated patients and suggested that SRSF2 mutation might have little impact on leukemic transformation [50]. This evidence concerns the gene SRSF2 and myelodysplastic syndrome.